Results of docetaxel plus oxaliplatin (DOCOX)±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study

Richards, Donald A.; Kocs, Darren M.; Spira, Alexander I.; McCollum, A. David; Diab, Sami; Hecker, Lanny I.; Cohn, Allen Lee; Zhan, Feng; Asmar, Lina

doi:10.1016/j.ejca.2013.04.022

Cited by 43 publications

(31 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Skin toxicity, namely an acneiform rash, was the most predominant side effect and considered to be dose-related for all HER-1/EGFR-targeted agents (32)(33)(34). However, only 1 patient developed mild (grade 1) local skin rash on the forearm in the present study.…”

Section: Discussionmentioning

confidence: 53%

Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma

Guo

Chen

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. This study was conducted to assess the efficacy and toxicity of nimotuzumab combined with radiotherapy (RT) in elderly patients with esophageal squamous cell carcinoma. The clinical data of 16 esophageal squamous cell carcinoma patients, aged >70 years, who were initially treated with nimotuzumab combined with RT, were collected and retrospectively reviewed. The overall response and treatment toxicity were analyzed using SPSS software.

show abstract

Section: Discussionmentioning

confidence: 53%

Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma

Guo

Chen

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…33,51 In our analysis targeted therapy plus conventional therapy showed a benefit in terms of OS in aGC patients compared to conventional therapy alone (pooled HR 0.823; 95%CI 0.743-0.912; p 0.001; Fig. 2A).…”

Section: Os Analysesmentioning

confidence: 93%

“…[25][26][27][28][29][30][31][32][33][34][35][36][37]44,[51][52][53][54][55][56][57][58][59] The TYTAN trial missed data about PFS. One trial missed results about OS.…”

Section: Studies Selectionmentioning

confidence: 99%

“…Two trials were analyzed only for RR and toxicity for missing data on survival endpoints. 33,51 Moreover, 3 trials, both designed for multiple arms comparison, were analyzed for single comparison considering an aggregate arm of different drug concentrations. 33,34,59 One trial was evaluated only for survival endpoints, because missing RR and toxicity data, as reported, an abstract in the meeting ASCO 2011.…”

Section: Studies Selectionmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?

Ciliberto

Staropoli

Caglioti

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

It is still uncertain if targeted therapy-based regimens in advanced gastric cancer actually produce survival benefit. To shed light on this important question, we performed a systematic review and meta-analyses on each relevant targeted-pathway. By searching literature databases and proceedings of major cancer meetings in the time-frame 2005-2014, 22 randomized clinical trials exploring targeted therapy for a total of 7022 advanced gastric cancer patients were selected and included in the final analysis. Benefit was demonstrated for antiangiogenic agents in terms of overall survival (HR 0.759; 95%CI 0.655-0.880; p < 0.001). Conversely no benefit was found for EGFR pathway (HR 1.077; 95%CI 0.847-1.370; p D 0.543). Meta-analysis of HER-2 pathway confirmed improvement in terms of survival outcome, already known for this class of drugs (HR 0.823; p D 0.004). Pooled analysis demonstrated a significant survival benefit (OS: HR 0.823; PFS: HR 0.762) with acceptable tolerability profile for targeted-based therapies as compared to conventional treatments. This finding conflicts with the outcome of most individual studies, probably due to poor trial design or patients selection. In conclusion, our findings demonstrate a significant survival benefit for targeted therapy in its whole, which can be ascribed to anti-angiogenic and anti-HER2 agents.

show abstract

“…In contrast, our own search yielded a total of 6777 records of which 45 [3][4][5] were RCTs. Of the 37 [3][4][5][6][7][8][9][10][11][12][13][14][15][16]19,20,[22][23][24][25][26][27][28][30][31][32][33][34][36][37][38]40,41,43,45,47,48 trials of cetuximab, 32 [3][4][5][6][8][9][10][11][12][14][15][16]…”

Section: Search Strategy and Missing Trialsmentioning

confidence: 99%

Letter to the editor

Sterrantino

Miroddi

Phillips

et al. 2016

Intl Journal of Cancer

View full text Add to dashboard Cite

Dear Editor, We are writing to bring serious concerns about the validity of the article "Hematologic toxicity assessment in solid tumor patients treated with cetuximab: A pooled analysis of 18 randomized controlled trials" 1 authored by Ran Cui et al. and recently published by the International Journal of Cancer to your attention. After careful reading, we firmly believe that the review uses inappropriate methods and incorrect data, and therefore that the conclusions are misleading.We should be clear that the reason that we have been able to consider the data so carefully is that our group is conducting a systematic review on serious thromboembolic adverse events which has a very similar design (PROSPERO registration number CRD42014009165 2 ), although our systematic review also includes randomized controlled trials (RCTs), in which panitumumab (another approved anti-EGFR monoclonal antibody) is tested as an add-on to standard regimens.We detail the many shortcomings of the research reported by Cui et al. below. Search Strategy and Missing TrialsWe were surprised by the small number of records (511) returned by the authors' initial search, the number of RCTS identified (18) and by the small number of articles that were excluded on grounds of lack of data (2). In contrast, our own search yielded a total of 6777 records of which 45 3-5,7-48 were RCTs. Of the 37 [3][4][5][6][7][8][9][10][11][12][13][14][15][16]19,20,[22][23][24][25][26][27][28][30][31][32][33][34][36][37][38]40,41,43,45,47,48 trials of cetuximab, 32 [3][4][5][6][8][9][10][11][12][14][15][16]19,20,[22][23][24][25][26][27][28][30][31][32][33][34][36][37][38]40,41,43,45,47,48 reported data on hematologic toxicities.Cui et al. do not report their search strategies in full, making it difficult to have confidence in their quality. From the information given, it would seem that although there are several rigorous search filters that can be used to identify RCTs, none of these were used in either MEDLINE or Embase. It also seems that the Cochrane Central Register of Controlled Trials was not used. The impact of these choices would be to restrict the number of articles identified by the literature searching.As of October 31, 2013, the time at which the literature search by Cui et al. was done, 6 of the additional 16 RCTs that we identified were already published. These 6 trials (including over 1,700 participants) should therefore have been identified and added to the 18 trials that they included (Table 1).To date, further data from >5,000 patients are available, as compared to the analysis of Cui et al.; around one-third of these data were already published at the time of their search, and therefore have been missed from the review.

show abstract

Results of docetaxel plus oxaliplatin (DOCOX)±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study

Cited by 43 publications

References 31 publications

Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma

Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma

A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?

Letter to the editor

Contact Info

Product

Resources

About